|
|
|
LifeScienceHistory.com - Check us out on Instagram
Take Your Next Career Step with Lundback
New Jersey Life Science Industry Directory
Banner Advertising
Please note that we have a new site: LifeScienceHistory.com, "Where history is made daily" under development and
delayed by COVID-19, to be launched in 2023 replacing New JerseyLifeScience.com. Regrettably, we are working with reduced
staffing and the current industry directory is no longer being maintained, but will be replaced with a new and improved
directory upon the launch of the new site. We apologize for the inconvenience.
Celator Pharmaceuticals, Inc.
| | | Phone: | (609) 243-0123 | Fax: | (609) 243-0202 | Year Established: | 2000 | Ticker: | CPXX | Exchange: | NASDAQ | Main Contact: | Derek Miller, CBO | | Other Contacts: | Matthew Young, Executive VP & CFO Karen Smith, M.D., Ph.D., M.B.A., CMO Bruce C. Cozadd, Chairman & CEO Craig C. Parker, Senior VP, Corporate Development Michael P. Miller, Seniopr VP, US Commercial Robert McKague, Senior VP & associate General Counsel
| | Company Description | Celator Pharmaceuticals, a subsidiary of Jazz Pharmaceuticals, is a pharmaceutical company developing new and more effective therapies to treat cancer. CombiPlex®,the company's proprietary drug ratio technology platform, represents a novel approach that identifies molar ratios of drugs that will deliver a synergistic benefit, and locks the desired ratio in a nano-scale drug delivery vehicle that maintains the ratio in patients with the goal of improving clinical outcomes. The company pipeline includes two clinical stage products, CPX-351 (a liposomal formulation of cytarabine:daunorubicin) for the treatment of acute myeloid leukemia and CPX-1 (a liposomal formulation of irinotecan:floxuridine) for the treatment of colorectal cancer; and preclinical stage product candidates, including CPX-571 (a liposomal formulation of irinotecan:cisplatin), and CPX-8, a hydrophobic docetaxel prodrug nanoparticle (HDPN) formulation being studied by the National Cancer Institute's Nanotechnology Characterization Laboratory.
On May 31, 2016, Jazz Pharmaceuticals and Celator Pharmaceuticals announced an agreement for Jazz Pharmaceuticals to acquire Celator for $30.25 per share in cash, or approximately $1.5 billion. | |
|
|
|
|
|